PMID- 37390478
OWN - NLM
STAT- MEDLINE
DCOM- 20240729
LR  - 20250203
IS  - 1531-1937 (Electronic)
IS  - 0897-1900 (Linking)
VI  - 37
IP  - 4
DP  - 2024 Aug
TI  - Administering a Soda Beverage With the Hepatitis C Treatment 
      Sofosbuvir/Velpatasvir and the Proton-Pump Inhibitor Pantoprazole: A Case Report.
PG  - 1011-1014
LID - 10.1177/08971900231183036 [doi]
AB  - Purpose: The manufacturer of sofosbuvir/velpatasvir recommends avoiding 
      coadministration with proton pump inhibitors (PPI) due to decreased velpatasvir 
      serum concentrations which could translate to an increased risk of HCV treatment 
      failure. A recent open-label study in healthy adults reported overcoming this 
      interaction through co-administration of velpatasvir and a PPI with soda, but 
      there is no clinical outcome data in HCV-infected patients. Summary: A 
      64 year-old male with a past medical history significant for decompensated 
      cirrhosis, chronic HCV infection, upper gastrointestinal bleed, anemia, 
      esophagitis, and previous HCV treatment failures required HCV treatment. The 
      patient's medications included a PPI but no other significant DDI were present. 
      The patient was instructed to take one sofosbuvir/velpatasvir tablet, soda, and 
      pantoprazole 40 mg tablet at the same time once daily. Treatment was well 
      tolerated, and clinical cure of HCV was achieved. Conclusion: Scenarios may arise 
      during HCV treatment that necessitate coadministration of a PPI. Interfering with 
      optimal absorption of HCV treatment could lead to development of resistance or 
      treatment failure. Future studies should include this strategy for overcoming 
      this common DDI. This case demonstrates sofosbuvir/velpatasvir administered 
      orally with soda and a PPI is potentially safe and effective for treatment of 
      chronic HCV infection.
FAU - Stark, Jennifer E
AU  - Stark JE
AUID- ORCID: 0000-0002-5957-782X
AD  - Veterans Healthcare System of the Ozarks, Fayetteville, AR, USA. RINGGOLD: 19964
FAU - Montgomery, Clarice M
AU  - Montgomery CM
AD  - Veterans Healthcare System of the Ozarks, Fayetteville, AR, USA. RINGGOLD: 19964
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20230630
PL  - United States
TA  - J Pharm Pract
JT  - Journal of pharmacy practice
JID - 8900945
RN  - 0 (Antiviral Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Benzopyrans)
RN  - 0 (Carbamates)
RN  - 0 (Drug Combinations)
RN  - 0 (Heterocyclic Compounds, 4 or More Rings)
RN  - D8TST4O562 (Pantoprazole)
RN  - 0 (Proton Pump Inhibitors)
RN  - WJ6CA3ZU8B (Sofosbuvir)
RN  - 0 (sofosbuvir-velpatasvir drug combination)
RN  - KCU0C7RS7Z (velpatasvir)
SB  - IM
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Antiviral Agents/administration & dosage
MH  - Benzimidazoles
MH  - Benzopyrans
MH  - Carbamates/administration & dosage
MH  - *Carbonated Beverages
MH  - Drug Combinations
MH  - Drug Interactions
MH  - Food-Drug Interactions
MH  - Hepatitis C, Chronic/drug therapy
MH  - Heterocyclic Compounds, 4 or More Rings/administration & dosage
MH  - *Pantoprazole/administration & dosage
MH  - *Proton Pump Inhibitors/administration & dosage
MH  - *Sofosbuvir/administration & dosage
OTO - NOTNLM
OT  - acid suppressive therapy
OT  - drug-drug interactio
OT  - hepatitis C virus
OT  - sofosbuvir/velpatasvir
COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2023/06/30 19:14
MHDA- 2024/07/29 12:42
CRDT- 2023/06/30 17:03
PHST- 2024/07/29 12:42 [medline]
PHST- 2023/06/30 19:14 [pubmed]
PHST- 2023/06/30 17:03 [entrez]
AID - 10.1177/08971900231183036 [doi]
PST - ppublish
SO  - J Pharm Pract. 2024 Aug;37(4):1011-1014. doi: 10.1177/08971900231183036. Epub 
      2023 Jun 30.